A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for treatment of metastatic breast cancer

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 994-1008

  Bender, Brendan ^a,c   Leipold, Douglas D ^a   Xu, Keyang ^a   Shen, Ben Quan ^a   Tibbitts, Jay ^b   Friberg, Lena E ^c  

^a GENENTECH INC   (United States)

^b UCB PHARMA   (Belgium)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

antibody drug conjugate; deconjugation; population pharmacokinetic model; T DM1; trastuzumab emtansine

Indexed keywords

TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST METASTASIS; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG STABILITY; DRUG TO ANTIBODY RATIO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; BREAST NEOPLASMS; EVALUATION STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLISM; METASTASIS; PATHOLOGY; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; MAYTANSINE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 84908356069     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9618-3     Document Type: Article

References (34)

1. Chen J, Jaracz S, Zhao X, Chen S, Ojima I. Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv. 2005;2(5):873-90. (Pubitemid 41488847)
2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-46. (Pubitemid 41486395)
3. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011;307(2):113-8.
4. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992;52(1):127-31.
5. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
6. Burris 3rd HA, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11(5):275-82.
7. Shen B-Q, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 2012;13:901-10.
8. Erickson HK, Phillips GL, Leipold DD, Provenzano CA, Mai E, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/ pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133-42.
9. Junttila TT, Guangmin L, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347-56.
10. Slikowski MX, Lofgre J, Lewis GD, Hotalin TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of Herceptin® (Trastuzumab). Semin Oncol. 1999;26(4 Suppl 12):60-70. (Pubitemid 29411434)
11. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29(9):2354-66.
12. Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, et al. Characterization of intact antibody-drug conjugates from plasma/plasma in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412:56-66.
13. Xu K, Liu L, Dere R, Mai E, Erickson R, Hendricks A, et al. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis. 2013;5(9):1057-71.
14. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2014;41:35-47.
15. Beal SL, Boeckman AJ, Sheiner LB, editors. NONMEM User's guide, part IV. San Francisco: University of California at San Francisco; 1988-1992.
16. Linbolm L, Pihlgren P, Jonsson EN. Psn-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57. (Pubitemid 41196689)
17. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. mAbs. 2011;3(1):61-6.
18. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-5. (Pubitemid 23211439)
19. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokin Pharmacodyn. 2001;28:507-32. (Pubitemid 34289541)
20. Shen B-Q, Xu K, Liu K, Raab H, Bhakta S, et al. Conjugation site modulated the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-9.
21. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012;14(4):799-805.
22. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huc242-dm1), and its two components inmice. J Pharmacol Exp Ther. 2004;308(3):1073-82. (Pubitemid 38263984)
23. Jumbe NL, Xim Y, Leipold D, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, and antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010;37(3):221-42.
24. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metatstatic breast cancer. Cancer Chemother Pharmacol. 2012;70(4):591-601.
25. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-70. (Pubitemid 39383058)
26. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-postive cancer. Clin Chemother Pharmacol. 2012;69(5):1229-40.
27. Gupta M, LoRusso PM, Wang B, Yi JH, Burris 3rd HA, Beeram M, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52(5):691-703.
28. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56(4):361-9. (Pubitemid 41095399)
29. Lu D, Joshi A, Wang B, Olsen S, Yi J-H, Krop IE, et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52(8):657-72.
30. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, et al. Site-specifi c conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925-32.
31. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34-45.
32. Valliere-Douglass JF, McFee WA, Salas-Solano O. Native intact mass determination of antibodies conjugated with monomethyl auristatin E and F at interchain cysteine residues. Anal Chem. 2012;84(6):2843-9.
33. Hengel SM, Sanderson RJ, Valliere-Douglass JF, Nicholas N, Leiske C, et al. Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal Chem. 2014. doi:10.1021/ac403860c.
34. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29.